CVS/pharmacy, American Diabetes Association sponsor diabetes campaign
WOONSOCKET, R.I. — CVS/pharmacy has announced that it is partnering with the American Diabetes Association as the sponsor of "A Day in the Life of Diabetes" campaign — a photo-sharing campaign on the ADA’s main Facebook page.
The CVS/pharmacy ExtraCare Advantage for Diabetes program will donate $1 to the American Diabetes Association for every photo or image uploaded, up to $25,000. CVS/pharmacy will also co-host a Twitter chat on Nov. 15 with Dr. Elizabeth Seaquist, VP medicine and science for the ADA.
"With 26 million people afflicted with the disease in the U.S. and an additional 79 million Americans at risk for Type 2 diabetes, this chronic condition has reached epic proportions," stated Papatya Tankut, VP pharmacy affairs at CVS Caremark. "By working together with the American Diabetes Association, we’re able to cast a wider net to help more people on their path to better health by sharing educational resources and spreading awareness of programs that can help them to manage diabetes and save money."
Additional activities happening during American Diabetes Month include:
Twitter Chat: To help educate CVS/pharmacy customers about diabetes and how to care for those with diabetes, CVS/pharmacy and the American Diabetes Association will co-host a live Twitter chat on the @CVS_Extra handle, featuring a CVS pharmacist and Seaquist for the ADA via the @AmDiabetesAssn handle. The Twitter chat will take place on Nov. 15, from 3 to 4 p.m. EST. Users that participate in the chat by using the #diabetesmonth or #CVSECAD hashtag, will automatically be entered to win prize packs from the CVS/pharmacy ExtraCare Advantage for Diabetes program.
ExtraCare Advantage for Diabetes Member Drive: The program is free and open to all members of the CVS/pharmacy ExtraCare savings and rewards program; cardholders can sign up at CVS.com/diabetes. Once enrolled, patients and caregivers gain access to:
- $5 coupon for joining’
- Monthly e-newsletter filled with recipes, tips and extra savings; and
- More than $130 in savings from Diabetes Health Magazine available through Dec. 31, 2012.
ExtraCare Advantage for Diabetes members earn ExtraBucks Rewards on more than 100 products used to manage diabetes, including testing supplies, glucose test strips and glucose meters. In addition to exclusive savings, members also have access to a variety of resources including an "Ask Our Pharmacist" section, additional offers, videos and recipes addressing their specific lifestyle needs. Members can log on to CVS.com/ExtraCare or access the CVS mobile app to view the personalized ExtraSavings and ExtraBucks Rewards that are currently available, and choose to "Print" or "Send to Card" their coupon savings and ExtraBucks Rewards.
In addition to earning ExtraBucks Rewards that can be spent on most items in the store, ExtraCare Advantage for Diabetes members receive special offers and discounts on their receipts and at the in-store ExtraCare Coupon Center.
Since its launch in 2010, the CVS/pharmacy ExtraCare Advantage for Diabetes program has helped more than 2 million members save money and better manage the disease.
Actos diabetes drug just received a dangerous black box warning The drug has been linked to Cancer http://spirithappy.org/wp/2011/10/02/type-2-diabetes-diet-actos-linked-to-cancer/
Watson to change brand in 2013
PARSIPPANY, N.J. – Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.
Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission earlier this month, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.
“When we announced the proposed acquisition of Actavis in April 2012, we immediately instituted an extensive and accelerated review of our global brand position and naming equities,” Watson president and CEO Paul Bisaro said. “A pioneer at the dawn of the U.S. Generic industry in 1984, the Watson corporate name was never registered globally. As we initiated our global expansion strategy in 2009, it became clear that we could not establish a single, unified market presence under the Watson brand.”
The rebranding will also include a redesign of the Actavis logo, created by branding firm Lippincott, which features a “W” emerging from an “A,” a reference to Watson.
The company also announced a new global generics commercial management team. Andrew Boyer, who joined Watson in 1998 as associate director of marketing in generics and served most recently as SVP sales and marketing, will lead the company’s U.S. Generics business. Jean-Guy Goulet, the president for Canada and Mexico for Watson’s Canadian subsidiary, Cobalt Pharmaceuticals, will lead the company’s Canadian and Latin American business. The company’s European, Asia, Middle East and Africa, and Australian businesses have new leaders as well.
Announcing its third quarter 2012 earnings Thursday, Watson said it had profits of $172.3 million, a 24.2% increase over third quarter 2011. Sales were $1.29 billion, an 18.8% increase over third quarter 2011, including $920.9 million in global generics sales.
No comments found
Walgreens, Alliance Boots form new jointly owned company: Walgreens Boots Alliance Development
DEERFIELD, Ill. — Walgreens on Tuesday announced that it has formally set up a new company, jointly owned with Alliance Boots, as part of their strategic partnership’s synergy program.
The new company, called Walgreens Boots Alliance Development, will be based in Bern, Switzerland.
No other details were released.
Walgreens and Alliance Boots first announced their proposed acquisition strategy in June and last month named CFO Wade Miquelon to an expanded and global leadership role as president of value creation services and international division. In that capacity, Miquelon serves as Wasson’s senior leader in collaborating with Alliance Boots management team to execute the new global strategic partnership.
At the time, Walgreens also named Robert Zimmerman, SVP international and international chief administration officer, as the lead executive for the Walgreens-Alliance Boots’ "synergy team." Former Wellpoint senior executive Brad Fluegel assumed the role of chief strategy officer at Walgreens.
As part of the Alliance Boots announcement in June, Walgreens stated that it expects combined synergies across both companies of between $100 million and $150 million in the first year and $1 billion by the end of 2016. To carry out a focused effort to capture those synergies, the company is setting up six new “global synergy teams” in Miquelon’s new organization that will work closely with Alliance Boots.
By 2016, the deal is projected to transform Walgreens from a $72 billion operator — with two-thirds of its revenue coming from its U.S. pharmacy business — to a $130 billion global health-and-wellness player.
For a comprehensive overview of Walgreens present business strategy, click here.
No comments found